scholarly journals Hepatitis C virus core antigen, an earlier and stronger predictor on sustained virological response in patients with genotype 1 HCV infection

2014 ◽  
Vol 14 (1) ◽  
Author(s):  
Bo Feng ◽  
Rui-Feng Yang ◽  
Qing Xie ◽  
Jia Shang ◽  
Fan-Yun Kong ◽  
...  
1994 ◽  
Vol 39 (9) ◽  
pp. 2022-2031 ◽  
Author(s):  
Shinjiro Sato ◽  
Shigetoshi Fujiyama ◽  
Motohiko Tanaka ◽  
Masafumi Goto ◽  
Yuko Taura ◽  
...  

2009 ◽  
Vol 200 (9) ◽  
pp. 1484-1485 ◽  
Author(s):  
Giorgio Antonucci ◽  
Claudio Angeletti ◽  
Francesco Vairo ◽  
Maria Antonella Longo ◽  
Enrico Girardi

2015 ◽  
Vol 9 (2) ◽  
pp. 215-220 ◽  
Author(s):  
Tatsuo Kanda ◽  
Masato Nakamura ◽  
Reina Sasaki ◽  
Shin Yasui ◽  
Shingo Nakamoto ◽  
...  

Direct-acting antivirals with or without peginterferon α (PEG-IFN α) plus ribavirin are now available for the treatment of hepatitis C virus (HCV) infection. Direct-acting antivirals are potent inhibitors of HCV replication, but some of them occasionally possess serious adverse events. We experienced a 64-year-old female with chronic HCV genotype 1b infection who showed elevated alanine aminotransferase of 528 IU/l at week 9 after the commencement of treatment of simeprevir with PEG-IFN α-2a plus ribavirin. However, she achieved sustained virological response at week 24 after the end of treatment. In Japan, we also have to treat elderly patients infected with HCV and/or advanced hepatic fibrosis. Until an effective interferon-free regimen is established, direct-acting antivirals with PEG-IFN plus ribavirin may still play a role in the treatment for certain patients. To avoid serious results from adverse events, careful attention and follow-up will be needed in the treatment course of simeprevir with PEG-IFN plus ribavirin for chronic HCV infection.


2017 ◽  
Vol 171 ◽  
pp. e223
Author(s):  
Marija Zeremski ◽  
Yang Chen ◽  
Roberto Zavala ◽  
Ype de Jong ◽  
Clewert Sylvester ◽  
...  

2013 ◽  
Vol 70 (11) ◽  
pp. 1006-1009 ◽  
Author(s):  
Velimir Kostic ◽  
Jelena Radovic ◽  
Jovana Djordjevic ◽  
Stevan Vujic

Background/Aim. Hepatitis C virus (HCV) infection is an important sociomedical problem worldwide because the chronification of the disease is frequent and the occurance of liver cirrhosis and hepatocellular carcinoma can be expected. The aim of this study was to determine the way of infection, pathohistological changes of the liver, virus genotype presence and sustained virological response after pegylated interferon and ribavirin therapy in prison inmates. Methods. The study included 52 patients with chronic HCV infection classified in two groups managed during 2008-2010. The first group consisted of prisoners (n = 22) and the second one of ?non-prisoners? (n = 30). The patients from both groups underwent diagnostic preparation (biochemical analyses, liver biopsy, hepatitis virus detection and genotypisation using polymerase chain reaction issue). The treatment lasted for 24 weeks for virus genotypes 2 and 3, and 48 weeks for genotypes 1 and 4. Results. All the patients were males, approximately the same age (35 ? 4.1 and 31 ? 7.6 years). Virus genotype 1 was significantly more frequent in the prisoners (p < 0.05), that demanded longer treatment (48 weeks). At the same time, statistically significant higher number of patients, ?non-prisoners?, achieved a sustained virological response (p < 0.01). Conclusion. Intravenous drug abuse and tattoos, separately or together, are the most frequent way of infection in prisoners. Dominant presence of virus genotype 1 resulted in lower number of patients with sustained virological response, probably regardless prison environment and regime.


Sign in / Sign up

Export Citation Format

Share Document